← FDA DRUG APPROVALS
FDA ANDA · ANDA205049
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Sponsor: XIROMED
APPLICATION
ANDA205049
TYPE
ANDA
ORIGINAL APPROVAL
2016-05-31
LATEST ACTION
2026-07-13
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATEDiscontinued
ETHINYL ESTRADIOL 0.01MG,0.01MG, NORETHINDRONE ACETATE 1MG,N/A · TABLET · ORAL
Approval history
2026-07-13Labeling · Supplement 6 · standardAP
2026-07-13Labeling · Supplement 5 · standardAP
2018-11-20Labeling · Supplement 2 · standardAP
2018-11-20Labeling · Supplement 1 · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.